Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
Clinical trial NCT06050928 · COMPLETED
Trial details
- NCT number
- NCT06050928
- Sponsor
- Escient Pharmaceuticals, Inc
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-30
- Primary completion
- 2024-10-22
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.